Nabriva Therapeutics (NASDAQ:NBRV) Trading Down 5%

Nabriva Therapeutics PLC – (NASDAQ:NBRV)’s stock price fell 5% during trading on Friday . The company traded as low as $1.97 and last traded at $1.89, 23,937 shares were traded during mid-day trading. A decline of 96% from the average session volume of 629,107 shares. The stock had previously closed at $1.99.

A number of brokerages have commented on NBRV. BidaskClub raised shares of Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. Bank of America set a $6.00 target price on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a report on Tuesday, August 20th. Needham & Company LLC restated a “buy” rating on shares of Nabriva Therapeutics in a report on Wednesday. Zacks Investment Research lowered shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 23rd. Finally, HC Wainwright set a $7.00 target price on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a report on Sunday, August 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $6.79.

The company’s fifty day moving average price is $1.93 and its 200-day moving average price is $2.20. The stock has a market cap of $1.45 billion, a P/E ratio of -1.17 and a beta of 2.42. The company has a debt-to-equity ratio of 0.56, a quick ratio of 5.67 and a current ratio of 5.67.

Nabriva Therapeutics (NASDAQ:NBRV) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. The firm had revenue of $6.92 million during the quarter, compared to analyst estimates of $1.23 million. Nabriva Therapeutics had a negative net margin of 910.45% and a negative return on equity of 157.79%. Analysts anticipate that Nabriva Therapeutics PLC – will post -1.1 earnings per share for the current fiscal year.

In other news, CEO Theodore R. Schroeder bought 50,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was purchased at an average price of $1.79 per share, for a total transaction of $89,500.00. Following the acquisition, the chief executive officer now owns 5,786 shares of the company’s stock, valued at $10,356.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders bought 64,977 shares of company stock valued at $119,951 and sold 21,773 shares valued at $45,186. 3.32% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sterling Investment Advisors Ltd. lifted its holdings in Nabriva Therapeutics by 100.0% during the 3rd quarter. Sterling Investment Advisors Ltd. now owns 20,000 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 10,000 shares in the last quarter. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in Nabriva Therapeutics during the 3rd quarter valued at about $40,000. A.R.T. Advisors LLC bought a new stake in Nabriva Therapeutics during the 2nd quarter valued at about $90,000. Creative Planning bought a new stake in Nabriva Therapeutics during the 3rd quarter valued at about $112,000. Finally, Parametric Portfolio Associates LLC lifted its holdings in Nabriva Therapeutics by 180.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 52,272 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 33,656 shares in the last quarter. Institutional investors own 3.90% of the company’s stock.

Nabriva Therapeutics Company Profile (NASDAQ:NBRV)

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Recommended Story: What is the Bid-Ask Spread?

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.